Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKinsey
Moodys
Cerilliant
UBS
Fish and Richardson
Medtronic
Federal Trade Commission
Novartis
Baxter

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,500,867

« Back to Dashboard

Summary for Patent: 6,500,867
Title: Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Abstract:An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Inventor(s): Virkki; Matti (Masala, FI), Vahervuo; Kari (Espoo, FI), Ritala; Marja (Espoo, FI), Partanen; Marja (Espoo, FI), Niskanen; Mervi (Espoo, FI), Lintulaakso; Jarmo (Espoo, FI), Laaksonen; Marja (Masala, FI), Kervinen; Lasse (Helsinki, FI), Kallioinen; Sari (Espoo, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/605,529
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Use; Process;

Drugs Protected by US Patent 6,500,867

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Orion Pharma STALEVO 150 carbidopa; entacapone; levodopa TABLET;ORAL 021485-003 Jun 11, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Orion Pharma STALEVO 50 carbidopa; entacapone; levodopa TABLET;ORAL 021485-001 Jun 11, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Orion Pharma STALEVO 75 carbidopa; entacapone; levodopa TABLET;ORAL 021485-005 Aug 29, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF PARKINSON'S DISEASE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,500,867

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Finland991485Jun 30, 1999

Non-Orange Book US Patents Family Members for Patent 6,500,867

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,797,732 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,500,867

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033796 ➤ Subscribe
Austria 245417 ➤ Subscribe
Australia 5830600 ➤ Subscribe
Australia 765932 ➤ Subscribe
Bulgaria 106251 ➤ Subscribe
Bulgaria 65364 ➤ Subscribe
Brazil 0011867 ➤ Subscribe
Canada 2378469 ➤ Subscribe
China 1168440 ➤ Subscribe
China 1358090 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Fuji
Harvard Business School
Federal Trade Commission
Cerilliant
Daiichi Sankyo
Deloitte
US Army
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot